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A set of 29 3-alkyl 5-arylimidazolidinediones (hydantoins) with affinity for the human
cannabinoid CB1 receptor was studied for their lipophilicity and conformational properties in
order to delineate a pharmacophore. These molecules constitute a new template for cannabinoid
receptor recognition, since (a) their structure differs from that of classical cannabinoid ligands
and (b) antagonism is the mechanism of action of at least three compounds (20, 21, and 23).
Indeed, in the [35S]-GTPçS binding assay using rat cerebellum homogenates, they behave as
antagonists without any inverse agonism component. Using a set of selected compounds,
experimental lipophilicity was measured by RP-HPLC and calculated by a fragmental method
(CLOGP) and a conformation-dependent method (CLIP based on the molecular lipophilicity
potential). These approaches revealed two models which differentiate the binding mode of
nonpolar and polar hydantoins and which could explain, at least for compounds 20, 21, and
23, the mechanism of action of this new family of cannabinoid ligands.
Introduction
Hashish and marijuana, two preparations derived
from the Indian hemp Cannabis sativa L., have been
used since an unknown number of centuries for their
medicinal and psychoactive properties. ¢9-Tetrahydro-
cannabinol (THC), the natural product isolated from the
plant,1 is its major psychoactive component. Cannab-
inoids, by definition, are compounds sharing a common
structure with THC; this class includes C21 compounds
originally isolated from Cannabis sativa L. as well as
their carboxylic acid derivatives, various analogues, and
transformation products. In vivo, THC is readily oxi-
dized to the more potent 11-OH-¢9-THC. Chemical
modifications of this structure have led to 9-nor-9â-OH-
hexahydrocannabinol (HCC), a compound exhibiting
enhanced analgesic activity. Pharmacomodulation of
THC and HHC gave bicyclic analogues,2 e.g., CP-47,-
497 and CP-55,940. The latter compound in tritiated
form became the first suitable radioligand for the
cannabinoid (CB) receptors.3
To date, two distinct cannabinoid receptors, CB1 and
the CB2, have been cloned. The CB1 cannabinoid recep-
tor,4,5 which was first evidenced by autoradiography and
radioligand binding studies using [3H]-CP-55,940, was
cloned from the human, rat, and mouse. It is expressed
in the brain and some peripheral tissues including
testis, ileum, urinary bladder, and vas deferens. An
alternative spliced form of the CB1 cannabinoid receptor,
named CB1A, has also been described, but so far has
revealed no peculiar property in terms of ligand recog-
nition and receptor activation.6 The CB2 cannabinoid
receptor was discovered by sequence homology.7 It is
predominantly found in the immune system (spleen,
tonsils, immune cells) and was cloned from the same
animal species.7-9 The amino acid sequence of both
cannabinoid receptors shows the common characteris-
tics of G-protein coupled receptors, including a lipophilic
7-transmembrane R-helix structure. The transduction
mechanisms of cannabinoid receptors involve inhibition
of cAMP production through inhibition of adenylate
cyclase,10 inhibition of calcium influx,11,12 activation of
potassium channels,13 and activation of the MAP kinase
pathway.14 Both types of cannabinoid receptors are
sensitive to pertussis toxin, suggesting their predomi-
nant coupling to Gi-type proteins (Gi and Go subtypes).
Endogenous ligands (called endocannabinoids) have
been discovered. These are long-chain polyunsaturated
fatty acids whose carboxylate group is amidated by
ethanolamine or esterified by glycerol.15 The major
representatives are anandamide or arachidonoyletha-
nolamide and 2-arachidonoylglycerol. The discovery of
endogenous ligands prompted further studies to eluci-
date the structural requisites and pharmacological
properties of CB1 and CB2 receptors. These studies
revealed that, in addition to classical cannabinoids,
other structurally quite different compounds are CB
receptor ligands. The term “cannabinoids” is now ap-
plied to any compound with good affinity for the
cannabinoid receptors. Cannabinoid ligands are cur-
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namely classical (e.g., ¢9-THC) and nonclassical can-
nabinoids (e.g., HHC), bicyclic cannabinoids (e.g., CP-
55,940), aminoalkylindoles (e.g., WIN-55,212-2), en-
docannabinoid analogues (anandamide and 2-arachi-
donoylglycerol), and diarylpyrazoles (e.g., SR-141716A
and SR-144528).
Based on the structure of 1-alkyl-3-(1-naphthoyl)-
pyroles and diarylpyrazoles antagonists, 24 3-alkyl-(5,5¢-
diphenyl)imidazolidinediones were recently synthesized
and evaluated as new CB1 cannabinoid receptor ligands.16
Five further compounds were prepared and assayed in
this work. These 3-alkyl-5-arylhydantoins could consti-
tute a novel template for CB1 recognition and possibly
CB1 antagonism. They are examined here for structure-
affinity relationships using the following approaches:
1. Binding studies to human CB1 obtained from
human CB1 transfected CHO cells membranes.16
2. Preliminary functional test for compounds exhibit-
ing the best affinity (compounds 20, 21, and 23). The
functional assay used was the [35S]-GTPçS binding
assay in rat cerebellum homogenates.
3. Lipophilicity determination by RP-HPLC of com-
pounds within the complete series of 29 ligands, conver-
sion into log P values as explained below, and compari-
son with calculated parameters (CLOGP, CLIP).17-18
4. Selection of the best lipophilicity predictor and its
application to the complete series of 29 hydantoins.
5. Search for qualitative relationships between lipo-
philicity and affinity.
6. Finally, these derivatives were compared with HHC
with a view to obtain a better understanding of the
stereoelectronic requisites of binding to the CB1 can-
nabinoid receptor. To address this issue, X-ray analysis,
molecular modeling, and molecular field superposition
methods were used.
Results and Discussion
Chemistry. The structures of the compounds used
in this study are presented in Tables 1 and 2. Synthesis
of compounds 1-24 (Table 1) has been described
elsewhere.16 Briefly, 5,5¢-diphenylhydantoin was first
obtained by the Biltz reaction from benzile, urea, and
KOH in ethanol. 5,5¢-Diphenylhydantoin was then alkyl-
Figure 1. Representative ligands of the cannabinoid recep-
tors.
Table 1. Structures, Affinity to CB1 Cannabinoids Receptors,
and Lipophilicity of 3-Alkyl-5,5¢-diphenylimidazolidinediones
1-24
compd R1 n R2
% of displacement
at 10 íMa lipophilicityb
1 H2 -N(CH2CH2)2O <5 2.16
2 H2 -N(CH2)5 <15 3.83
3 H2 -N(CH3)2 <5 2.83
4 H2 -CH3 <20 3.84
5 H3 -CH3 25.1 ( 2.2 4.26
6 H4 -CH3 35.4 ( 2.9 4.80
7 H5 -CH3 35.6 ( 1.5 5.37
8 H7 -CH3 61.2 ( 4.7 6.50
9 H1 -C6H5 40.6 ( 3.9 4.11
10 H0 -CH(CH3)2 <5 2.89
11 CH3 2 -N(CH2CH2)2O 23.9 ( 1.9 3.49
12 CH3 5 -CH3 46.8 ( 3.9 6.48
13 CH3 6 -CH3 51.3 ( 3.8 7.04
14 OCH3 2 -N(CH2CH2)2O 21.7 ( 1.7 2.73
15 OCH3 5 -CH3 66.6 ( 5.3 5.81
16 F2 -N(CH2CH2)2O 30.3 ( 2.1 2.81
17 F5 -CH3 40.6 ( 3.1 5.81
18 F6 -CH3 51.4 ( 2.9 6.42
19 F7 -CH3 62.5 ( 5.7 6.94
20 Br 2 -N(CH2CH2)2O 91.2 ( 7.3 3.86
21 Br 3 -OH 88.4 ( 6.7 3.76
22 Br 5 -CH3 72.1 ( 5.3 6.87
23 Br 6 -CH3 89.2 ( 7.6 7.45
24 Br 7 -CH3 80.0 ( 6.0 7.99
a Results are expressed as the percentages of the displaced
specific binding of [3H]SR-141716A (mean ( SEM, n ) 3-5).
b Lipophilicity was calculated using the CLIP method.
Table 2. Structures, Affinity to CB1 Cannabinoids Receptors,
and Lipophilicity of Other (()-3-Alkyl-5-arylimidazolidinediones
25-29
compd n R
% of displacement
at 10 íMa lipophilicityb
25 3 -CH3 <5 2.21
26 5 -CH3 28.8 ( 2.3 3.21
27 2 -C6H5 64.0 ( 5.6 2.31
28 3 -C6H5 44.3 ( 3.8 2.80
29 1 naphthyl 59.8 ( 5.1 2.92
a,b See Table 1.
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in K2CO3/dimethylformamide. The new analogues 25-
29 differing in the 5-substituents were obtained after
adaptation of the previously described procedure,16 as
outlined in Scheme 1. Although these reactions are
rather straightforward, their success depends on a good
temperature control and a correct proportion of alkyl-
ating agent. For example, the alkylation of 5,5¢-diphen-
ylhydantoin by 1-chloroheptane with potassium carbon-
ate gave an N1,N3-dialkyl and an N3,O-dialkyl product
in addition to the desired mono-N3-alkyl product (Scheme
2). Selectivity in the alkylating step is obtained at low
temperature, which may explain the somewhat low
yields observed. Moreover, the tryptophan analogues
25-29 have a center of chirality (Table 2) and were not
obtained in enantiopure form. The first synthetic step,
i.e., the formation of the indolylmethyl-hydantoins,
retained the absolute configuration of the starting
amino acid, i.e., D-o rL-tryptophan. However, the
subsequent alkylating process gave a racemate ([R] )
0), and compounds 25-29 were tested as racemates.
Pharmacology. Compounds 1-29 were screened at
10 íM in competitive binding displacement experiments
with [3H]-SR-141716A, a selective CB1 cannabinoid
radioligand, in a preparation of transfected CHO mem-
branes expressing the human CB1 cannabinoid receptor.
The results (Tables 1 and 2) are expressed as a percent-
age of displacement of the specific binding of [3H]-SR-
141716A. The most active compounds were then com-
pared to reference cannabinoids (HU-210, CP-55,940,
SR-141716A, and WIN-55,212-2) in dose-displacement
curves. Under our conditions, saturation experiments
gave a Kd of 1.24 ( 0.1 nM and a Bmax of 47.9 ( 4.7
pmol/mg protein. The Ki of the most active compounds
are presented in Table 3. Compounds 20, 21, and 23
exhibited interesting Ki values below 100 nM. Neither
the addition of 50 íM5 ¢-guanylylimidodiphosphate
(GppNHP),16 a stable analogue of GTP, nor the use of
[3H]-CP-55,940 as radioligand (data not shown) signifi-
cantly affected the affinity of compounds 20, 21, and
23 for the human CB1 cannabinoid receptor. Taken
together, these data suggest that the cannabinoid
hydantoins, at least compounds 20, 21, and 23,d on o t
act as agonists for the cannabinoid receptor. Indeed, it
is known that agonists of G-protein coupled receptors
are sensitive to the addition of stable analogue of GTP.19
In addition, Kearn and co-workers20 have shown that
[3H]-SR 141716A labels both the active and inactive CB1
cannabinoid receptors, in contrast to the agonist radio-
ligand, [3H]-CP-55,940, suggesting the use of the latter
may reveal higher affinity in the case of agonists. The
commercially available radiolabeled guanosine 5¢-O-(ç-
[35S]thio)triphosphate [35S]-GTPçS was used in a de-
rived binding technique to further characterize the
activity of compounds 20, 21, and 23 as widely used for
cannabinoid receptors (for a review, see ref 21). This
assay constitutes a functional measure of the interaction
of the receptor and the G-protein, the first step in
activation of the G-protein coupled receptors. In addi-
tion, whatever the transduction mechanism, it is pos-
sible to define the functional activity of a ligand as
agonist (positive intrinsic activity), partial agonist
(partial positive intrinsic activity), antagonist (no in-
trinsic activity), or inverse agonist (negative intrinsic
activity). In rat cerebellum homogenates which present
a high density of CB1 cannabinoid receptors, HU210
stimulates the [35S]-GTPçS binding with an Emax of 267
( 10% (full agonist) and an EC50 of 3.0 (1.2-7.8) nM,
whereas SR-141716A shows inverse agonist property as
it decreases nucleotide binding by 30.5 ( 2.1% (Figure
2A). Compounds 20, 21, and 23 were without intrinsic
effect but competitively inhibit HU 210-induced [35S]-
GTPçS binding in rat cerebellum homogenates (pKB
values of 6.11 ( 0.14, 6.25 ( 0.06, and 5.74 ( 0.09,
respectively) (Figure 2B).
Lipophilicity. The RP-HPLC method was first cali-
brated with reference compounds of well-known log P
values ranging from 0.64 to 3.30 (benzamide, benzyl
alcohol, acetanilide, benzaldehyde, phenol, nitroben-
zene, benzene, toluene, chlorobenzene, bromobenzene,
benzophenone, and naphthalene).22 The RP-HPLC log
kw indices were correlated with the corresponding log
Scheme 1a
a Reagents: (a) KCNO, water, 80 °C, 30 min; (b) HCl, ethanol,
reflux 2 h; (c) RCl, K2CO3, DMF, room temperature overnight.
Scheme 2a
a Reagents: (a) chloroheptane, K2CO3, DMF.
Table 3. Ki Values of Compounds 20, 21, and 23 and
Reference Cannabinoid Ligands for Human Cannabinoid CB1
Receptors
compd
Ki (nM) against
[3H]SR-141716A
20 70.3 ( 4.3
21 103.2 ( 6.8
23 97.9 ( 5.5
HU210 0.82 ( 0.04
CP 55940 5.2 ( 0.3a
SR-141716A 8.9 ( 0.4a
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This regression equation was used to transform the
measured capacity factors (log kw) of a set of 11 hydan-
toins (Table 4) into log P values. Two computational
methods (CLOGP17 and CLIP18) were then applied to
predict the lipophilicity of this set of hydantoins. The
resulting log P values were compared to the experimen-
tal values (Table 4). CLOGP yielded a good correlation
(n ) 11, r2 ) 0.82, s ) 0.78, F ) 38.49), but a better
correlation was obtained with CLIP (n ) 11, r2 ) 0.89,
s ) 0.58, F ) 72.35). This method was thus applied to
the complete set of hydantoins, and the log P values so
calculated were examined for relationships with the CB1
receptor affinity data (Tables 1 and 2).
Structure-Affinity Relationships. The results
reported in Table 1 show that affinity for the CB1
receptor increases with the introduction of a para
substituent on the phenyl rings. The dibromo deriva-
tives showed the highest affinity. For the nonpolar
hydantoins (i.e., 7, 12, 15, 17, and 22), CB1 affinity
decreased in the following order Br > OMe > F > Me >
H, whereas such a relationship was not observed for the
polar hydantoins (i.e., 11, 14, 16, 20).
On the basis of these results, various modifications
were carried out at position N3 of the hydantoin moiety
(Table 1). It turned out that whatever the nature of the
R1 substituent, CB1 affinity increased with increasing
length of the alkyl group and hence with lipophilicity.
For example, compound 8 showed a higher CB1 affinity
than compound 4. However, the case of compounds 20-
23 is not straightforward. Compounds 20-21 have a
remarkably low log Pcalc value in contrast with com-
pound 23 (Table 4), yet their CB1 affinity was higher
(Table 1). This would suggest that lipophilicity of the
side chain at position N3 alone does not explain varia-
tions in CB1 affinity, and that the CB1 receptor can also
accommodate ligands having a polar moiety (hydroxy
or morpholino group) on this chain, as demonstrated by
compounds 20-21. Finally, no displacement of the
radioligand at 10 íM was observed with compounds 2
and 3, suggesting that the introduction of a basic amino
group on the alkyl side chain is unfavorable to CB1
binding.
X-ray Analysis. Two independent molecules (mol100
and mol200) are found in the asymmetric unit of the
crystal structure of compound 20. They form a dimer
connected by a H-bond between N5 and O1 (OâââN
distance about 3.2 Å, see Table 5), suggesting that these
groups could form intermolecular interactions with the
CB1 receptor. An ORTEP diagram of the two molecules
in the asymmetric unit of the crystal cell is presented
in Figure 3, and selected geometries are given in Table
5. As expected, the hydantoin rings are planar, with the
N and C atoms adopting an sp2 hybridization. Bond
lengths within the ring are intermediate between single
and double bonds, implying electronic delocalization in
the system.
The perpendicular orientation of the two bromophenyl
rings is similar in both molecules, allowing optimal ð-ð
and quadrupole interactions in the crystal packing. The
morpholino ring adopts a stable chair conformation in
both independent molecules (mol100 and mol200) while
the conformation adopted by the lateral ethylmorpholino
group differs in both molecules (see ô1, ô 2, ô 3 in Table
5).
Binding Mode Hypothesis and Molecular Field
Calculation. The previous synthesis of HHC and
Figure 2. Comparative effects of cannabinoids and com-
pounds 20, 21, and 23 on the stimulation [35S]-GTPçS binding
in rat cerebellum homogenates. (A) Effects of HU-210 (2) (full
agonist), SR141716° () (inverse agonist), 20 (3), and 23 (O)
(full antagonists) on [35S]-GTPçS binding. Data are the mean
from at least three separate experiments; vertical lines show
SEM. (B) Determination of pKB values of 20, 21, and 23
against HU 210-induced [35S]-GTPçS binding in rat cerebellum
membranes. The HU 210 stimulation (from 10-5 to 10-10.5 M)
curve is presented in the absence (9) or presence of compounds
20 (1), 21 (2), and 23 ([) (30 íM). Data are the mean from at
least three separate experiments; vertical lines show SEM.
log P ) 1.31((0.13)log kw - 0.362((0.25)
(r
2 ) 0.92, n ) 12, s ) 0.28, F ) 107.1)
Table 4. Determination of the Lipophilicity of 12
Representative Compounds: Comparison between
Experimental Measurements and Calculations
compd log Kw log Pcorr CLIPa CLOGPb
2 4.11 5.02 3.83 2.94
3 3.00 2.94 2.83 1.58
4 2.93 2.86 3.84 3.31
5 3.46 3.44 4.26 3.84
7 4.32 4.39 5.37 4.90
20 4.50 4.59 3.86 3.45
22 6.14 6.39 6.87 6.62
23 6.65 6.95 7.45 7.15
25 2.35 2.22 2.21 2.27
26 3.17 3.13 3.21 3.33
29 3.08 3.03 2.92 3.52
a Reference 18. b Reference 17.
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on the structural requirements of cannabinoid affinity,
namely (1) a hydrophobic C3 alkyl side chain (SC), (2) a
phenolic group (PH), and (3) the northern aliphatic
hydroxy group (NAH) (Figure 4). Furthermore, experi-
mental evidence has indicated that the pyran oxygen
is not part of this model and can be replaced by a carbon
or nitrogen atom, or removed ring with opening, without
extensive loss of potency2 (see CP-47,497 and CP-55,-
940).
Molecular lipophilic potential (MLP)18 and molecular
hydrogen bonding potentials23 studies have allowed us
here to establish the elements by which hydantoin
derivatives could interact with the CB1 receptor. The
preferred conformation of the analogues were defined
using the solid-state structures of compound 20 (mol100)
(Figure 3). The torsion angles ô1, ô2, and ô3 (Table 5)
were adjusted by hand on the templates defined by the
solid-state structures of compound 20 (mol100, Table
5) to obtain consistent conformations through the series,
and the structures were energy-minimized by molecular
mechanics calculations. The MLP generated by these
analogues was then calculated using the CLIP pro-
gram.18 The results confirm the known differences in
log P values between the polar hydantoins (i.e., having
a morpholino or hydroxy group on the alkyl side chain)
and their nonpolar analogues. As depicted in Figure 5,
two important hydrophobic regions separated by a small
polar region exist in nonpolar hydantoins, whereas only
one polar and one hydrophobic region are generated
around the polar hydantoins (11, 15, 16, 20, 21). For
both families of hydantoins (i.e., polar and nonpolar),
an important hydrophobic region is generated around
the phenyl rings. The MLP generated around HHC
(Figure 5) was also calculated and is characterized by
one important hydrophobic region (blue), located on the
hydrophobic C3 alkyl side chain (Figure 5), and one
small polar region (red) located near the phenolic and
northern aliphatic hydroxy groups (Figure 5). Examina-
tion of the MLPs suggests that HHC and hydantoins
could be stabilized within the active site of the CB1
receptor by their hydrophobic C3 alkyl side chain or
phenyl rings, respectively.
A new computational tool known as the molecular
hydrogen bonding potentials23 (MHBPs) was also used
to identify the groups potentially able to contribute to
Table 5. Selected Geometries of the X-ray Structure of
Compound 20
mol 100 mol 200
Bond Lengths (Å)
O1-C2 1.215(3) 1.219(3)
C2-N3 1.352(2) 1.352(2)
N3-C4 1.402(2) 1.407(3)
C4-N5 1.347(3) 1.344(3)
N5-C6 1.460(3) 1.458(3)
C6-C2 1.547(3) 1.546(3)
C4-O7 1.213(3) 1.212(3)
Bond Angles (deg)
O1-C2-N3 126.7(4) 127.0(4)
C2-N3-C4 112.0(4) 111.8(3)
N3-C4-N5 107.4(3) 107.3(4)
C4-N5-C6 112.7(4) 112.7(4)
N5-C6-C2 100.6(3) 100.5(4)
C6-C2-N3 107.0(4) 107.0(4)
N3-C4-O7 124.4(4) 123.8(4)
Torsion Angles (deg)
ô1 69.9(5) 102.8(4)
ô2 58.7(5) -60.5(5)
ô3 -161.5(4) -75.5(5)
Figure 3. ORTEP diagram (50% probability) obtained from
the X-ray structure of 20 showing the association of the two
molecules in the asymmetric unit.
Figure 4. Distances measured on the three-point HHC
pharmacophore, namely SC, the hydrophobic alkyls side chain;
PH, the phenolic group, and NAH, the northern aliphatic
hydroxy group.
Figure 5. Molecular lipophilic potential of 20, 21, 23, and
HHC. The polar regions are represented in red and the
nonpolar in blue.
1752 Journal of Medicinal Chemistry, 2002, Vol. 45, No. 9 Ooms et al.the binding by H-bond formation. The MHBPs involve
the same stepwise procedure as used previously to
generate the MLP. First, a H bonding fragmental
system (Systahl version 1.0) derived from literature
donor (R) and acceptor (â) values identifies the struc-
tural elements (polar hydrogen atoms and lone pairs)
able to form H-bonds and assigns a fragmental value
to each of them. The MHBPs are then calculated for
each point k on a molecular surface or in a 3D-grid
according to eq 1
where k is the label of the point in space, Nfrg the
number of molecular fragments in the compound, nat
the number of polar atoms in the molecular fragment i,
Fij the R and/or â value of atom j in the fragment i, djk
the distance between the polar atom j and the point k,
f(djk) the distance function, Ujk the angle defined by the
point k, the polar atom j, and the polar hydrogen or the
lone pair belonging to the polar atom j, and g(Ujk) the
angular function.23 This new computational tool was
compared with GRID interactions energies24 and has
been used successfully in structure-absorption rela-
tions.23
For both families of hydantoins (i.e., polar and non-
polar), two H bond-accepting potentials appear around
the carbonyls (Figure 6). A third hydrogen accepting
potential is also generated by the morpholino and
hydroxy groups present in polar hydantoins (Figure 6).
The analysis of HHC shows that H-bond accepting
potentials are generated around the phenolic group, the
northern aliphatic hydroxyl, and the oxygen heteroatom
of the furan ring (Figure 6).
Molecular Superposition. Examination of the MH-
BPs and MLP of hydantoins and HHC (Figures 5 and
6) shows that the three pharmacophoric groups in HHC
(Figure 7) match the corresponding groups in the polar
hydantoins, namely (1) the oxygen atom of the mor-
pholino or hydroxy moiety, (2) the oxygen atom of the
carboxyl amide, and (3) the phenyl rings (Figure 7). On
the basis of these similarities, structural alignment
between the polar hydantoins and HHC was achieved
by root-mean-square (rms) fitting. As depicted in Figure
8, the polar hydantoins and HHC, although structurally
different, can optimally be aligned. The Connoly surface
generated by the compounds were then calculated using
this superposition. In this view, one can see that the
overall shape of HHC is closely mimicked by the
superposed hydantoins. It appears that the Connoly
surfaces of the morpholino group is confined to a region
that would be predicted to permit pharmacological
activity (i.e., there does not appear to be hydantoins
volume at the C9-C11 position that has previously been
associated with decreased cannabinoid potency). Fur-
thermore, it appears that pro-R phenyl ring fits well
with the alkyl side chain of HHC, whereas pro-S phenyl
ring generates steric hindrance. This suggests that the
CB1 affinity of our compounds could be improved by a
more appropriate subsitution of the C1 position of the
hydantoin. However, the pro-S phenyl ring could also
be responsible of the pure antagonist profile of com-
pounds 20, 21, and 23. Indeed, according to Arie ¨n’s
theory, the modulation of the agonist to antagonist
activity can be obtained through the addition of some
supplementary aromatic rings that play the role of
additional binding sites (e.g., the passage from musca-
rinic agonists to muscarinic antagonists or from GABA
agonists to GABA antagonists25).
Alignment was also investigated for HHC and the
nonpolar hydantoins, using two pairs of atoms (i.e., the
hydantoin carbonyls and the oxygen atoms in rings A
and B of HHC), revealing two distinct superimpositions
Figure 6. Molecular hydrogen bonding potential of 20, 21,
23 and HHC. Red, magenta, and yellow iso-potential contours
correspond to three levels of values (acceptor MHBPs: 0.15,
0.10, and 0.05).
MHBPk )å
i)1
Nfrg
å
j)1
nat
Fij f(djk) g(Ujk) (1)
Figure 7. (A) Groups (i.e., SC, PH, NAH) used for the
superposition of compounds 20-21 and HHC. (B) Alignment
obtained from the RMS fitting between HHC and 20, and
orthogonal views of the Connoly surfaces calculated on 20
(gray) and HHC (dark gray). (C) Alignment obtained from the
RMS fitting between HHC and 21, and orthogonal views of
the Connoly surfaces calculated on 21 (gray) and HHC (dark
gray).
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5 by the fact that the MLP generated around the
nonpolar hydantoins is characterized by two important
hydrophobic regions separated by a small polar one. As
shown by the Connoly surfaces (Figure 8), the best
alignment corresponds to orientation 2. Indeed, the two
phenyl rings in the hydantoins are well aligned with
HHC rings, and the alkyl side chains are optimally
aligned. Such a close alignment was not obtained with
orientation 1, since the alkyl side chain of 23 does not
fit well with the northern aliphatic hydroxy of HHC and
the pro-R phenyl ring generates steric hindrance (Figure
8). Although HHC is an agonist and hydantoins are
antagonists, several authors26-28 suggest a common
pharmacopohore for cannabinoid ligands whatever the
full, partial, or inverse agonist properties of the ligand.
In the absence of site directed mutagenesis data giving
a clue about the amino acids involved in the hydantoin
recognition on one hand and of a 3-D structure of the
CB1 receptor on the other hand, the superimposition of
hydantoins to HHC was made in a first intention.
These results suggest that the polar hydantoins adopt
a binding mode (orientation 1) different from that of
nonpolar hydantoins (orientation 2). This dual binding
mode is consistent with the fact that the presence of a
hydroxy on the C9 position of HHC is not essential for
affinity.2 It is also in agreement with the SAR results,
since CB1 affinity of nonpolar hydantoins decreases in
the order Br > MeO > F = Me > H, whereas for polar
hydantoins such ranking was not observed. Further
ligands bearing only one aromatic ring in position 5 are
under study to confirm this model and improve the
affinity while retaining antagonism.
Conclusion
The comparison of the molecular lipophilic potential
and the molecular hydrogen bond potential generated
around hydantoins and HHC has led to a superimposi-
tion model for this new class of CB1 ligands and probable
antagonists. This model suggests that there are key
elements common to HHC and hydantoins and that
these compounds are stabilized within the active site
of the CB1 receptor through hydrophobic and H-bond
interactions. The superimposition model also addresses
the unfavorable steric interaction generated by the
substituents on the hydantoin ring. Rational synthesis
of further ligand is under progress to enhance the CB1
affinity of this new class of compounds and to confirm
this three-point CB1 binding mode hypothesis.
Compounds 20, 21, and 23 represent the first neutral
antagonists of the cannabinoid receptors. Regarding the
originality of structure and of mechanism of action, they
may constitute new pharmacological tools as well as
potential therapeutic agents in the control of appetite,
learning, and memory.
Experimental Section
Chemistry. Melting points were determined on a Bu ¨chi
SMP 20 capillary instrument and are uncorrected. The purity
of the compounds was checked by TLC on aluminum-covered
plates of siliga gel Merck 60F254 and by RP-HPLC (Perkin-
Elmer 100-LC with LC-85B UV detector set at 254 nm and
Integrator LCI-100) using a C18 HL 90-5S Bio-Rad column
(250 mm, internal diameter 4.6 mm, particles size 5 íM), a
mobile phase consisting of methanol and phosphate buffer pH
7.4, and a flow rate of 1 mL/min. Infrared spectra were
recorded as KBr pellets using a Perkin-Elmer 297 spectrom-
eter. Absorption values are expressed as wavenumbers (cm-1).
Elemental analyses were performed on a Carlo Erba EA 1108
Analyzer (Carlo-Erba, Milano, Italy) and are within (0.4% of
the theoretical values. 13C NMR were recorded at ambient
temperature on a AC-300 Bruker spectrometer. The chemical
shifts are reported as ä (ppm) values relative to tetramethyl-
silane. Mass spectra were recorded on a Varian MAT 44 S (E.I.
70 eV, source 200 °C), with the kind help of Prof. G. Scriba
(Iena University, Germany). Optical rotations were measured
using a Perkin-Elmer 241 MC polarimeter operating at 589
nm and room temperature.
Preparation of 3-Alkyl-(5,5¢-diphenyl)imidazolidinedi-
ones (1-24). The N-3-substituted(5,5¢-diphenyl)hydantoins
1-24 were synthesized as described elsewhere.16
Preparation of 3-Alky-5-(indo-3-yl)imidazolidinedi-
ones (25-29). To a solution of 0.01 mol of the 5-(indol-3-yl-
methyl)imidazolidinedione (prepared as previously described)29
in DMF in the presence of 0.04 mol of potassium carbonate
was added 0.012 mol of the respective alkyl chloride, and the
solution was stirred overnight at room temperature. The
product was obtained after addition of water, and the precipi-
tate was recrystallized from ethanol. 5-(Indol-3-yl-methyl)-
imidazolidinedione was prepared from tryptophane (0.146 mol)
and potassium isocyanate (0.493 mol) in 200 mL water. The
mixture was stirred and heated at 80 °C for 30 min. After
cooling, 70 mL of 6 M HCl was added to precipitate the
hydantoic acid. The latter gave the desired cyclic compound
Figure 8. (A) Groups (i.e., SC, PH, NAH) used for the
superposition of compounds 23 and HHC. (B) (orientation 1)
Alignment obtained from the RMS fitting between HHC and
23, and orthogonal views of the Connoly surfaces calculated
on 23 (gray) and HHC (dark gray). (C) (orientation 2) Align-
ment obtained from the RMS fitting between HHC and 23,
and orthogonal views of the Connoly surfaces calculated on
23 (gray) and HHC (dark gray).
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of 3 M HCl and 0.2 L of ethanol. The resulting precipitate was
recrystallized in propan-2-ol.
5-(Indol-3-yl-methyl)imidazolidinedione: yield 77%; mp
249-251 °C (uncorrected); mass spectrometry [M¥] ) 238,
[M¥+1] ) 239; 13C NMR ä (DMSO-d6) 26.76(CH2), 58.55(CH),
108.23, 111.46, 118.56, 118.82, 121.07, 124.35, 127.74, 136.15-
(C and CH arom.), 157.64(CdO), 175.98(CdO).
(()-3-Butyl-5-(indo-3-yl)imidazolidinedione (25): yield
65%; mp 142-144 °C (uncorrected); mass spectrometry [M¥]
) 285, [M¥+1] ) 286; 1H NMR ä (DMSO-d6) 0.76(t,3H), 1.01-
(m,4H), 3.10(d,2H), 3.40(t,2H), 4.32(d, 1H), 7.11-8.16(m, 5H),
10.88(s, 1H); 13C NMR ä (DMSO-d6) 13.32(CH3), 18.84(CH2),
26.51(CH2), 29.19(CH2), 36.92(CH2), 56,82(CH), 107.41, 111.08,
118.19, 118.57, 120.71, 124.22, 127.40, 135.88(C and CH
arom.), 156.86(CdO), 173.94(CdO). Anal. (C16H19N3O2)C ,H ,
N.
(()-3-Hexyl-5-(indo-3-yl)imidazolidinedione (26): yield
61%; mp 135-137 °C (uncorrected); mass spectrometry [M¥]
) 313, [M¥+1] ) 314; 1H NMR ä (DMSO-d6) 0.82(t,3H), 1.21-
(m,8H), 3.05(d,2H), 3.55(t,2H), 4.33(d, 1H), 6.93-7.79(m,d,d,
5H), 10.85(s, 1H); 13C NMR ä (DMSO-d6) 12.92(CH3), 20.16-
(CH2), 23.76(CH2), 24.94(CH2) 25.41(CH2), 29.02(CH2), 35,62-
(CH2), 55.95(CH), 105.79, 109.47, 116.56, 116.95, 119.08,
122.63, 125.79, 134.26(C arom.), 155.24(CdO), 172.35(CdO).
Anal. (C18H23N3O2), C, H, N.
(()-3-Ethylphenyl-5-(indo-3-yl)imidazolidinedione (27):
yield 79%; mp 159-161 °C (uncorrected); mass spectrometry
[M¥] ) 333; 1H NMR (CDCl3) 3.19(d,1H), 4.07(s,1H), 4.57(d,-
1H), 6.95-7.98(m, 10H); 13C NMR (CDCl3) 24.40(CH3), 42.36-
(CH2), 44.88(CH2), 58.86(CH), 108.06, 111.23, 118.56, 119.79,
122.21, 123.06, 127.34,127.44, 128.02, 128.23, 135.57, 135.83-
(C arom), 156.70(CdO), 172.57(CdO). Anal. (C20H19N3O2)C ,
H, N.
(()3-Propylphenyl-5-(indo-3-yl)imidazolidinedione (28):
yield 75%; mp 153-155 °C (uncorrected); mass spectrometry
[M¥] ) 347, [M¥+1] ) 348; 1H NMR (CDCl3) 1.76(q,2H), 2.48-
(t,2H), 3.03(d,2H), 3.40(t,2H), 4.21(d, 1H), 7.01-8.03(m,d,d,s,
5H), 10.76(s, 1H); 13C NMR (CDCl3) 27.80(CH2), 29.09(CH2),
32.82(CH2), 38.36(CH2), 57.75(CH2), 109.32, 111.33, 118.62,
119.87, 122.43, 123.15, 125.99, 127.04, 128.29, 128.37, 136.18,
141.09(C and CH arom.), 157.55(CdO), 173.66(CdO). Anal.
(C21H21N3O2)C ,H ,N .
(()-3-(1-Naphthylmethyl)-5-(indo-3-yl) imidazolidinedi-
one (29): yield 56%; mp 176-178 °C (uncorrected); mass
spectrometry [M¥] ) 369, [M¥+] ) 370; 1H NMR (DMSO-d6)
3.06(d,2H), 3.97(s,2H), 4.29(d,1H), 6.41-8.41(m,12H), 10.91-
(s,1H); 13C NMR (DMSO-d6) 26.44(CH2), 40.52(CH2), 57.76-
(CH2), 107.8, 111.49, 118.69, 119.03, 121.14, 123.15, 124.76,
127.28, 136.17(C and CH arom)indol., 122.92, 125.42, 125.94,
126.40, 126.81, 127.83, 128.60, 130.16, 131.23, 133.14 (C and
CH arom.)napht, 156.74(CdO), 174.13(CdO). Anal. (C23H19N3O2)
C, H, N.
Pharmacology. Fatty acid free bovine serum albumin
(fafBSA) was purchased from Sigma Chemical Co (St. Louis,
MO). WIN-55,212-2 was purchased from RBI (Natick, MA),
HU-210, and CP-55,940 from Tocris (Bristol, U.K.). SR-
141716A was kindly donated by Sanofi Recherche (Montpellier,
France). [3H]-SR-141716A (1.92 TBq/mmol, 52 Ci/mmol) was
from Amersham (Roosendaal, The Netherlands).
1. Inhibition of [3H]-SR-141716A Binding in CB1-
Transfected CHO Cells. CB1-transfected CHO cells,5 kindly
donated by Prof. Vassart (Universite ￿ Libre de Bruxelles) and
Dr. Nokin (Euroscreen, Brussels), were maintained in culture
using Ham F12 medium (Gibco BRL) containing 10% fetal calf
serum, 100 íg/mL streptomycin, 100 U/mL penicillin, and 200
íg/mL G418 (Gibco BRL). Membranes (60 íg) obtained from
transfected CHO cells expressing human CB1 cannabinoid
receptors were incubated in siliconized plastic tubes at 30 °C
w i t h1n M[ 3H]-SR-141716A for1hi n5 0m MTris-HCl (pH
7.4) with 3 mM MgCl2, 1 mM disodium EDTA, and 0.1% bovine
serum albumin (BSA). Nonspecific binding was determined
with 10 íM WIN-55,212-2o r1 0íM CP-55,940. Finally, the
membrane was rapidly filtered on 0.5% polyethylemeneimine
(PEI) pretreated GF/C glass fiber filters (Whatman) and
washed twice with 5 mL of ice-cold incubating buffer without
serum albumin. Radioactivity on filters was measured with a
Pharmacia Wallac 1410 â-counter by liquid scintillation in 10
mL of Aqualuma. Assays were performed in triplicates.
2. Binding of [35S]GTPçS in Rat Cerebella Membranes.
The binding experiment was performed at 30 °C in plastic
tubes containing 20 íg of protein resuspended in 1 mL (final
volume) of binding buffer (50 mM Tris-HCl (pH 7.4), 5 mM
MgCl2, 1 mM disodium EDTA, 100 mM NaCl, 0.1% (w/v)
bovine serum albumin) supplemented with 20 íM GDP and
0.01 nM-100 íM agonist or antagonist. The binding was
initiated by the addition of [35S]-GTPçS (0.05 nM final
concentration). Incubations were performed for 1 h and were
terminated by addition of 3 mL of ice-cold washing buffer (50
mM Tris-HCl, pH 7.4; 5 mM MgCl2; 1 mM disodium EDTA;
100 mM NaCl). The suspension was immediately filtered
through GF/B filters using a 24-well Brandel cell harvester
and washed twice with ice-cold binding buffer. Radioactivity
trapped on the filters was counted as mentioned above. The
nonspecific binding was measured in the presence of 0.1 mM
Gpp(NH)p.
Data Analysis. Radioligand and nucleotide binding data
were analyzed by nonlinear regression with the software
GraphPad Prism, version 3.00 (GraphPad, San Diego, CA).
Antagonist equilibrium dissociation constants (expressed as
pKB) were calculated using the following equation
where A is the concentration of antagonist used and CR is the
ratio of EC50 values for the agonist measured in the presence
or in the absence of the antagonist, respectively.
Structural, Physicochemical, and Computational In-
vestigations. 1. Crystal Structure. Single crystals of com-
pound 20 were obtained by slow evaporation of concentrated
solutions in ethanol. A suitable crystal was mounted on a
quartz fiber on a goniometer head of a CAD4 Nonius diffrac-
tometer. After determination of the cell parameter using 25
well-centered reflections, complete diffraction data sets were
collected. The structure was solved using direct methods and
refined by full matrix least squares on F2 using the program
Shelxl97.30 All non-hydrogen atoms were treated anisotropi-
cally while a riding model was applied for the hydrogens.
Analytical correction for absorption was introduced.
Compound 20: triclinic, P-1, a ) 12.382(2) Å, b ) 12.718(2)
Å, c ) 14.438(2) Å, R)112.31 (1)°, â ) 92.73 (1)°, ç ) 92.30-
(1)°, V ) 2096.1 (2) Å3, Z ) 2 (two molecules in the asymmetric
unit), í ) 5.14 mm-1, Dx ) 1.627 g cm-3, ì (Cu KR) ) 1.54178
Å, F(000) ) 1048, T ) 290 K, 8229 unique reflections (Rint )
0.0166), R1 ) 0.0444 for 7500 Fo > 4ó(Fo), R1 ) 0.0483 for all
data (8229) and wR2 ) 0.1356, GOF ) S ) 1.075.
2. Molecular Models and Calculation of Molecular
Interaction Fields. All calculations were performed on
Silicon Graphics Indy R4400 175 MHz, O2 R5000 180 MHz,
or Origin 2000 4âR10000 195 MHz workstations using the
SYBYL 6.5 molecular modeling package (Tripos Associates,
St. Louis, MO) including SLN (Sybyl line notation) and
CONCORD (connectivity to coordinates) algorithm.31
The starting geometries of the hydantoins and HHC were
built by CONCORD. The C3 alkyl side chain of HHC was
oriented perpendicularly to the aromatic ring by adjusting both
the ô1 and ô2 torsion angles to 60° and 120°, respectively. These
values correspond to one of the four low-energy conformations
previously identified by Xie et al.32 The torsion angles ô1, ô2,
and ô3 of hydantoins were adjusted using the solid-state
structure of compound 20 (mol1 100, see Table 5). Each
structure was then energy-optimized using the MMFF94s force
field including MMFF94 partial atomic.33,34 As a test, the
geometry of compound 20 was first optimized and proved in
good agreement with the experimental crystal structures.
The molecular lipophilic potential18 and molecular hydrogen
bonding potentials23 were calculated on the solvent accessible
surface area.
KB ) A/(CR - 1)
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HPLC. Because the log P value of the investigated compounds
could not be determined by the traditional shake-flask method,
lipophilicity indices were measured by a reversed-phase HPLC
method (RP-HPLC) consisting in a Perkin-Elmer Series 10 LC
apparatus linked to a Perkin-Elmer LCI-100 integrator and a
UV Perkin-Elmer detector set at 250 nm. The capacity factors
were measured with a Bio RAD Bio Sil C18 HL 90-5S column
(length 250 mm, internal diameter 4.6 mm, and particles size
5 íM) with four different mobile phases (methanol/phosphate
buffer 0.1 M pH 7.4 ratios ) 90:10, 80:20, 75:25, and 70:30
v/v). The capacity factor (k¢) was defined for each mixture as
the (tr - t0)/t0 where tr is the retention time of the solute, and
t0 the column dead time. The log kw corresponding to the
logarithm of the apparent capacity factor for a concentration
of methanol of 0% was then obtained by linear extrapolation
of experimental log k¢ values.35-36.
4. Calculation of log P Values. Two different procedures
were used to calculate the log P of the hydantoin derivatives
(Tables 1-3), namely the CLOGP algorithm17 and the MLP
using the CLIP program.18 In the MLP calculations, the input
geometry of compound 20 was that of its X-ray structure,
whereas the structure of the other compounds was optimized
by molecular mechanics.
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